Clinical

CNTN1 and NRXN3 clearly differentiated severe and milder forms of spinal muscular atrophy (SMA).

A poster presented at the CHEST 2024 annual meeting shows that inhaled treprostinil (iTRE) reduces hospitalizations in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD).

A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.

Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer.

Medical experts explore the psychological and emotional aspects of decision-making for patients in the third-line stage of metastatic colorectal cancer, recommend involving support services like social work or palliative care, and discuss the caregiver’s role in supporting patients through these psychosocial challenges.

Panelists discuss how type 2 inflammatory diseases can lead to potential long-term complications or comorbidities, including airway remodeling in asthma, nasal polyps in chronic rhinosinusitis, skin thickening in atopic dermatitis, and increased risk of cardiovascular issues and metabolic disorders.

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in patients with severe asthma and asthma with concurrent chronic obstructive pulmonary disease (COPD).

At the CHEST 2024 annual meeting, international respiratory society leaders highlighted the need for global collaboration to address issues like air pollution and health equity in respiratory care.

Capivasertib, in combination with venetoclax, produced promising responses in preclinical models of diffuse large B-cell lymphoma (DLBCL).

Recent results from a new diabetes reversal program demonstrate the reliable, sustained benefits of nonpharmacological interventions in the management of diabetes and overall health of patients.

Experts at CHEST 2024 highlighted significant racial disparities in lung cancer screening, treatment, and outcomes, recommending system-based interventions to improve care equity for patients of color.

A phase 3b study found that Black individuals who switched to bictegravir/emtricitabine/tenofovir alafenamide were able to maintain virologic suppression after 72 weeks.

Experts at the CHEST 2024 annual meeting agreed that artificial intelligence (AI) should not be relied upon entirely, but instead be used as a tool by radiologists to make a diagnosis of interstitial lung disease (ILD).

Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.

Medical experts examine strategies for care coordination in high-risk patients with cardiometabolic conditions.

Panelists discuss how recent clinical trial results for emerging HER2-directed therapies, including findings from the SOHO-01 study, inetetamab/pyrotinib combination study, and Beamion LUNG-1, are shaping the future landscape of NSCLC treatment, while also highlighting other noteworthy developments presented at this year’s World Conference on Lung Cancer.

Key opinion leaders explore educational initiatives aimed at enhancing guideline adherence in cardiometabolic risk management, emphasizing effective tactics for improving health outcomes.

Panelists discuss how clinicians carefully weigh the efficacy of HER2-directed therapies against their safety profiles, particularly focusing on managing serious adverse events like interstitial lung disease, while also considering emerging strategies to combat resistance to these treatments as research in the field progresses.

Although air pollution is linked to increased exacerbations in patients with idiopathic pulmonary fibrosis (IPF), its role in disease progression remains uncertain, with evidence suggesting that both genetic susceptibility and environmental factors contribute to IPF development.

Caroline Quill, MD, of the University of Rochester Medical Center, highlighted the potential of artificial intelligence (AI) and digital technologies to enhance treatment for chronic obstructive pulmonary disease (COPD) at the CHEST 2024 annual meeting in Boston, Massachusetts.

Researchers identify certain predictive factors that impact the prognosis of patients with myasthenia gravis and COVID-19 infection.

In recent years, it’s been estimated that 10% to 28% of patients with myeloid disorders develop adult onset inflammatory and autoimmune disorders (IADs), complicating treatment.

Higher pre- and postdiagnosis Alternate Mediterranean Diet (AMED) scores are associated with improved overall survival in patients with ovarian cancer.

Initial evidence suggests alternative approaches such as exercise, dietary modification, and psychosocial therapies may enhance traditional management of pulmonary hypertension.

Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on tyrosine kinase inhibitor (TKI) therapy were able to avoid relapse despite discontinuing therapy.

B-cell activating factor receptor chimeric antigen receptor (CAR) T-cell therapy caused cytotoxic effects on all chronic lymphocytic leukemia (CLL) cell lines.

Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical parameters.

Parth Rali, MD, Temple University Hospital, is looking forward to approaching pulmonary vascular diseases as a spectrum, especially when assessing pulmonary embolism and pulmonary hypertension, at CHEST 2024.

The researchers have detailed their complete findings of subcutaneous (SC) vs intravenous (IV) efgartigimod in generalized myasthenia gravis (gMG) from the phase 3 ADAPT-SC trial and initial findings from the open-label extension of the study, ADAPT-SC+.

Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.